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Abstract: Background: the apicomplexan parasite Neospora caninum causes important reproductive
problems in farm animals, most notably in cattle. After infection via oocysts or tissue cysts,
rapidly dividing tachyzoites infect various tissues and organs, and in immunocompetent hosts, they
differentiate into slowly dividing bradyzoites, which form tissue cysts and constitute a resting stage
persisting within infected tissues. Bumped kinase inhibitors (BKIs) of calcium dependent protein
kinase 1 are promising drug candidates for the treatment of Neospora infections. BKI-1294 exposure of
cell cultures infected with N. caninum tachyzoites results in the formation of massive multinucleated
complexes (MNCs) containing numerous newly formed zoites, which remain viable for extended
periods of time under drug pressure in vitro. MNC and tachyzoites exhibit considerable antigenic
and structural differences. Methods: Using shotgun mass spectrometry, we compared the proteomes
of tachyzoites to BKI-1294 induced MNCs, and analyzed the mRNA expression levels of selected
genes in both stages. Results: More than half of the identified proteins are downregulated in MNCs
as compared to tachyzoites. Only 12 proteins are upregulated, the majority of them containing SAG1
related sequence (SRS) domains, and some also known to be expressed in bradyzoites Conclusions:
MNCs exhibit a proteome different from tachyzoites, share some bradyzoite-like features, but may
constitute a third stage, which remains viable and ensures survival under adverse conditions such as
drug pressure. We propose the term “baryzoites” for this stage (from Greek βα%υσ = massive, bulky,
heavy, inert).
Keywords: antigenic variation; chemotherapy; drug adaptation; drug resistance
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1. Introduction
The phylum Apicomplexa parasites includes important pathogens for humans and animals.
Among those, Neospora caninum, which is closely related to Toxoplasma gondii, causes abortion, stillbirth
or birth of weak offspring in cattle, sheep and other ruminants, and also infects a wide range of other
species [1]. Canines act as definitive hosts of N. caninum, and sexual development of the parasite in the
intestinal tissue leads to the formation of oocysts, which are shed with the feces. Canines can also act
as intermediate hosts and are affected by neurological symptoms [2]. Three stages are important for
the life cycle of N. caninum, sporozoites, tachyzoites, and bradyzoites. Sporozoites develop within the
oocysts and are orally infective. Tachyzoites represent the rapidly proliferating disease-causing stage,
which infects numerous cell types and tissues, and can also cross the placenta and affect the developing
fetus, which leads to malformations and/or abortion. The slowly proliferating bradyzoites are formed
upon the immunological and physiological host response, and they represent a tissue cyst-forming
stage that persists within infected tissues for extended periods. A temporal immunomodulation,
such as during pregnancy, frequently leads to recrudescence and re-differentiation into tachyzoites
which infect the developing fetus [3]. No vaccine is currently licensed for the prevention of bovine or
canine neosporosis, and specific immuno- or chemotherapeutical treatments are lacking [4,5]. As a
consequence, there is a keen interest in novel chemotherapeutics acting on specific targets [6].
Examples for such targets are calcium-dependent protein kinases (CDPKs). The genes coding
for these kinases originate from plants [7], and therefore constitute interesting drug targets. During
the last decade, CDPK1 has been an important focus as a target for drug development against a
wide range of apicomplexans such as Plasmodium falciparum, Toxoplasma gondii, Neospora caninum,
Sarcocystis neurona, Besnoitia besnoiti, Babesia bovis, Theileria equi and Cryptosporidium parvum [7,8].
Bumped kinase inhibitors (BKIs) are ATP-competitive kinase inhibitors that target CDPK1 in different
apicomplexans [9]. They exhibit a high degree of efficacy and specificity for apicomplexan CDPK1
and are optimized to fit into a hydrophobic pocket within the ATP binding site. BKIs inhibit the
ATP binding activity of a range of CDPK1 isoforms, including those of N. caninum [10]. They were
shown to block invasion of invasive stages into host cells [10] and also inhibit microneme secretion,
and thus invasion and egress [11]. Several BKIs have been studied so far with respect to efficacy against
N. caninum infection, among them the pyrazolopyrimidine BKI-1294. This compound has shown
highly promising efficacy in pregnant mouse models for neosporosis [12] and for toxoplasmosis [13],
and in a pregnant sheep model for toxoplasmosis [14]. Moreover, other BKIs are effective against
neosporosis, as shown in pregnant mouse [15] and sheep [16] models.
BKI-1294 does not act parasiticidal in vitro [17]. Prolonged exposure of mammalian cells infected
with different Neospora isolates (Nc-1, Nc-Liv, and Nc-Spain7) and with the T. gondii strains RH and
ME49 results in the formation of intracellular multinucleated complexes (MNCs) [12,17]. In addition, we
found that BKI-1294-induced MNCs exhibited a deregulated gene expression pattern, as evidenced by
the simultaneous expression of bradyzoite and tachyzoite antigens [12]. Immunofluorescence staining
showed that the formation of MNCs during extended BKI-1294 treatment was accompanied by a lack
of SAG1 surface expression and a decreased CDPK1 expression, and the formation of numerous zoites
incapable of disjoining from each other. Following drug removal, proliferation continued, and zoites
lacking NcSAG1 emerged from the periphery of these complexes, forming infective tachyzoites after
10 days [18]. These results suggested that MNCs could constitute a drug-induced resting stage that
assures the survival of the parasite until the drug pressure is released.
To address this question, we have chosen proteomics as an appropriate tool. A number
of studies had been carried out on the proteome of N. caninum previously. As one of the first
methods, 2-D-Differential Gel electrophoresis (DIGE) was applied to define proteomic changes during
tachyzoite-to-bradyzoite differentiation, identifying 20 proteins upregulated in tachyzoites and 6 in
bradyzoites. However, this approach had technical limitations in that membrane proteins were not
very well resolved [19]. Furthermore, proteomics was applied to identify potential virulence factors as
exemplified by a study compared two isolates, namely Nc-Spain1H (low virulence) and Nc-Spain7
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(high virulence) during different steps of the lytic cycle [20]. To investigate BKI-1294-induced MNCs in
more detail, we thus compared the proteomes of isolated tachyzoites to the proteomes of MNCs by
shotgun mass spectrometry.
2. Materials and Methods
2.1. Tissue Culture Media, Biochemicals, and Drugs
If not stated otherwise, all tissue culture media were purchased from Gibco-BRL (Zürich,
Switzerland), and biochemicals from Sigma (St. Louis, MO, USA). BKI-1294 was synthesized to >99%
purity by HPLC and NMR by Wuxi AppTech, Inc. (Wuhan, China) and provided by the Center for
Emerging and Reemerging Infectious Diseases (CERID), Division of Allergy and Infectious Diseases,
Department of Medicine, University of Washington (Seattle, WA, USA), and was stored in powder
form, dry and protected from light at room temperature. For in vitro studies, 20 mM stock solutions
were prepared in dimethyl sulfoxide (DMSO) and they were stored at −20 ◦C. Primers for real-time
PCR (RT-PCR) were purchased from Eurofins (Luxemburg, Luxemburg).
2.2. Host Cell Cultivation and Parasite Maintenance
Human foreskin fibroblasts (HFF; ATCC® SCRC-1041™) were maintained in Dulbecco’s modified
Eagle medium (DMEM), containing phenol red, supplemented with 10% heat-inactivated and fetal
calf serum (FCS), 100 U of penicillin/mL, and 100 µg streptomycin/mL. The Neospora caninum-Spain7
(Nc-Spain7) isolate was maintained by infecting semi-confluent HFF monolayers and cultivated at
37 ◦C and 5% CO2, with passages once or twice per week as previously described [21]. For induction
of the formation of MNCs, N. caninum infected HFF were treated with 5 µM BKI-1294 during 4–6 days.
2.3. Microscopy
Transmission electron microscopy (TEM) of BKI-1294-treated or non-treated Nc-Spain7-infected
HFF was done as previously described [12,17]. In short, infected monolayers grown in T-25 tissue
culture flasks were fixed in 2.5% glutaraldehyde in 100 mM sodium cacodylate buffer pH 7.3, removed
from the flask by scraping, post-fixed in 2% osmium tetroxide in cacodylate buffer, and sequentially
dehydrated in a graded (30-50-70-90-100%) ethanol series. Specimens were embedded in Epon 812
epoxy resin, polymerized at 65 ◦C, and ultrathin sections were cut on a Reichert and Jung ultramicrotome
(Reichert & Jung, Vienna). Following transfer onto 300 mesh formvar-carbon coated nickel grids (Plano
GmbH, Marburg, Germany), they were stained in Uranyless™ and lead citrate (EMS, Hatfield, PA,
USA), and specimens were inspected on a CM12 TEM operating at 80 kV.
For scanning electron microscopy (SEM), semi-confluent HFF monolayers were maintained in
T175 cell culture flasks and were infected with Nc-Spain7 tachyzoites. At 4 h post infection, treatments
with 5 µM BKI-1294, or the corresponding amount of DMSO in controls were initiated, and cultures
were maintained at 37 ◦C/5% CO2 during 3 (controls) or 6 days (BKI-1294-treated cultures), until MNCs
were formed. Subsequently, the infected monolayers were washed twice with PBS, followed by removal
of infected cells with a rubber cell scraper and resuspension in PBS. After passaging the suspensions
twice through a 25-gauge needle to break the host cells, MNCs and tachyzoites were separated from
host cell debris by Sephadex G-25 chromatography. The parasite fractions in the flow through were
collected by centrifugation (15 min, 1000× g, 4 ◦C), washed twice with PBS, and were fixed in 2.5%
glutaraldehyde and 2% osmium tetroxide, and dehydrated in ethanol as for TEM. They were finally
washed twice in hexamethyl-disilazane (HDS), taken up in a small volume of HDS, and were allowed
to settle onto glass coverslips under a fume hood. They were then sputter-coated with gold and
inspected on a JEOL 840 SEM operating at 25 kV.
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2.4. Proteomics
Semi-confluent HFF monolayers were maintained in T175 cell culture flasks, and were infected
with Nc-Spain7 tachyzoites. At 4 h post infection, treatment with 5 µM BKI-1294, or the corresponding
amount of DMSO in controls, was initiated, and cultures were maintained at 37 ◦C/5% CO2 during 3
(controls) or 6 days (BKI-1294-treated cultures), until multinucleated complexes (MNCs) were formed.
Subsequently, the infected monolayers were washed twice with PBS, followed by removal of infected
cells with a rubber cell scraper and resuspension in PBS. After passaging the suspensions twice through
a 25 gauge needle to break the host cells, MNCs and tachyzoites were separated from host cell debris
by Sephadex G-25 chromatography. The parasite fractions in the flow through were collected by
centrifugation (15 min, 1000× g, 4 ◦C) and washed twice with PBS, as described [21].
Cell pellets were lysed in 100 µL 8M urea/100 mM Tris/HCl pH 8/cOmpleteTM protease inhibitor
cocktail (Roche Diagnostics, Rotkreuz, Switzerland) by incubation for 15 min at RT followed by 15 min
in an ultrasonic water bath. Proteins were reduced and alkylated with 10 mM DTT for 30 min at
37 ◦C and 50 mM iodoacetamide for 30 min at 37 ◦C. Proteins were precipitated at −20 ◦C by addition
of 5 volumes cold acetone and incubation at −20 ◦C overnight. All liquid was carefully removed,
and the pellet dried in ambient air for 15 min before reconstitution of proteins in 200 µL of 8 M urea,
50 mM Tris-HCl pH 8.0. Protein concentration was determined by Bradford assay and an aliquot
corresponding to 10 µg protein was digested by trypsin (1:50 trypsin/protein ratio) for 6 hours at 37 ◦C
after dilution of urea concentration to 1.6 M with 20 mM Tris-HCl pH 8.0 and 2 mM CaCl2. The digests
were acidified with TFA (1%) and analyzed by LC-MS/MS. Three repetitive injections of an aliquot
corresponding to 500 ng of protein digest was separated on an EASY-nLC 1000 coupled to a QExactive
mass spectrometer (ThermoFisher Scientific). Peptides were trapped on an Acclaim PepMap100 C18
pre-column (3 µm, 100 Å, 75 µm × 2 cm, ThermoFisher Scientific, Reinach, Switzerland) and separated
by backflush on a C18 column (3 µm, 100 Å, 75 µm × 15 cm, Nikkyo Technos, Tokyo, Japan) by applying
a 60 min gradient of 5% to 40% acetonitrile in water and 0.1% formic acid, at a flow rate of 400 nL/min.
Peptides of m/z 360–1400 were detected with resolution of 70,000, applying an automatic gain control
(AGC) target of 106 and a maximum ion injection time of 50 ms. A top ten data dependent method for
precursor ion fragmentation with a stepped 27% normalized collision energy was applied with the
following settings: precursor isolation width of 2 m/z, resolution 17,500, AGC of 105 with a minimum
target of 103, maximum ion time of 110 ms, charge exclusion of unassigned and 1+ ions, peptide match
on, and dynamic exclusion for 20 s, respectively.
2.5. Measurement of RNA Expression Levels by Quantitative Reverse Transcriptase Real-Time PCR
To determine the RNA levels of selected N. caninum genes (see Table 1), quantitative reverse
transcriptase RT-PCR was performed as described [12,22]. Briefly, 8 × 104 HFF/well were seeded
onto 6 well plates and cultured for 4 days at 37 ◦C/5% CO2 prior to infection with 6 × 105 N. caninum
tachyzoites/well. At 4 h post infection, the supernatant was aspirated and replaced with fresh medium
containing either 5 µM BKI-1294 to form MNCs, or the corresponding amount of DMSO to generate
tachyzoites. At 3 days post infection in the case of tachyzoites or 6 days post infection in the case
of MNCs, RNA was isolated using the Nucleospin® RNA Plus RNA isolation kit (Machery-Nagel,
Düren, Germany) followed by cDNA synthesis using the Promega GoScript-Kit (Promega, Madison,
WI, USA) according to the instructions provided by the manufacturers. Quantitative RT-PCR was
performed using the Corbett Rotor gene 6000 (Qiagen, Venlo, Netherlands). The reactions contained
10 µL Sybr-Green-Mix, 0.1 µL of the forward and reverse primers listed in Table 1 and 10 µL of cDNA.
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Table 1. List of primers used in this study.
Annotation Accession No Primer Sequence
Nc28SrRNA L49389.1
Nc28S_F TCTCTCTCACCAGGTTTAGG
Nc28S_R CCGTGTTTCAAGACGGGTC
Bradyzoite antigen, putative (BAG1) NCLIV_027470
NcBAG1_F CTCGACTTCATGGATGAGG
NcBAG1_R CTTCTATGGTAACGTCATCC
Calcium dependent protein kinase 1 NCLIV_011980
NcCDPKI_F AGACGCTGCTATCGCGGG
NcCDPKI_R TTAGTTTCCGCAAAGCTTCAG
Inner membrane protein 1 NCLIV_031770
IMC1_F GGATGGGACGGCGGTG
IMC1_R CGCCACCGGCTGGATG
SRS-domain containing protein NCLIV_019580
Nc019580_F CGCGTGCTCGGCGTGG
Nc019580_R GTGCTACCAGTTTGCATCC
2.6. Statistics
The MS data were obtained from three biological replicates, with two technical replicates for
each biological replicate. All MS data were processed by MaxQuant (version 1.5.4.1) with matching
between runs for the same strain activated, but not between different strains, in order to avoid
over-interpretation of the data. The sample sets were interpreted separately by MaxQuant. Fragment
spectra were interpreted against a recent N. caninum protein sequence database in fasta format
(ToxoDB-44_NcaninumLIV_AnnotatedProteins.fasta). The trypsin cleavage rule allowed amide
bond cleavage after lysine and arginine but not if a proline follows, up to three missed cleavage
sites, fixed carbamidomethylation modification of cysteines, variable oxidation of methionine and
acetylation of protein N-termini. Precursor and fragment mass tolerances were set to 10 and 20 ppm,
respectively. Peptide spectrum matches and peptide and protein group identifications were filtered
to a 1% false discovery rate (FDR) based on reversed database sequence matches, and a minimum
of two razor or unique peptides were required to accept a protein group identification. Protein
identifications considered as contaminations (e.g., trypsin or BSA) as well as proteins identified only
by site (considered by MaxQuant developers as very likely false positives) were removed for statistical
validation. The normalized label-free quantification (LFQ) protein group intensities as calculated by
MaxQuant and the sum of the three most intense peptide intensities were used for relative proteome
quantifications. First, we imputed missing protein LFQ values for samples in any condition group
when there were at least two LFQ intensities in one group (downshift of 1.8 S.D. with a width of
0.3 S.D. [23]). Before summing, missing peptide intensities were imputed sample group wise, when
there were at least 2 valid intensities (downshift of 1.8 S.D. with a width of 0.3 S.D.). The resulting
protein intensities were named iTop3. This process left proteins without values in one or the other
group. For Welch's T-tests, those missing protein intensities were replaced by imputed values from
the very low end of intensity distributions in analogy to the above described imputation strategy
(downshift 1.8 S.D., width of 0.3 S.D.). An FDR-controlled Benjamini-Hochberg procedure was used for
correction of p-values. A log2-fold change of at least 1 and a corrected p-value of ≤0.05 were required
to be considered as significant. Statistical testing and imputation were made with a homemade R
(version 3.6.2 script run under R-Studio).
3. Results
3.1. Formation of MNCs upon BKI-1294 Treatment In Vitro
Treatment of N. caninum infected HFF with 5 µM BKI-1294 lead to the formation of intracellular
MNCs within 3–6 days, which are comparatively visualized with non-drug-treated tachyzoites in
Figure 1. TEM of non-treated tachyzoites showed intracellular parasites undergoing endodyogeny,
situated within a parasitophorous vacuole (Figure 1A). Figure 1C shows an MNC that formed after
6 days of treatment with BKI-1294. These MNCs were also located within a parasitophorous vacuole,
were structurally intact, viable, and exhibited the typical features of apicomplexan parasites, but were
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not able to disconnect from each other and thus remained intracellular. SEM was performed on MNCs
and non-treated tachyzoites that were separated from host cell debris by Sephadex G25 chromatography
(Figure 1B,D). MNCs exhibited multiple newly formed apical complexes that emerged out of the MNC
surface, as indicated in Figure 1D.
Figure 1. Tachyzoites (A,B) and BKI-1294 induced MNCs (C,D). (A,C) are TEM micrographs, with
A showing individual tachyzoites situated within a parasitophorous vacuole, and© an MNC with
multiple nuclei (nuc). Also visible are mitochondria (mito), rhoptries (rop), and apical complexes
protruding from the MNC (black arrows). (B,D) are SEM micrographs of isolated tachyzoites and
an MNC, respectively. Note the multiple apical complexes protruding from the surface of the MNC
indicated by white arrows. Bar in (A) = 1 µm; bars in (B–D) = 1.2 µm.
3.2. The Proteome of Multinucleated Complexes Is Different from the Proteome of Tachyzoites
Shotgun mass spectrometry of the proteomes of N. caninum tachyzoites and of BKI-induced
MNCs resulted in the identification of 207,041 unique peptides matching to 2558 proteins (Table 2).
The complete dataset is given in Table S1, which is available online.
Table 2. Summary of protein quantification data. N. caninum tachyzoites and MNCs were grown,
purified and subjected to MS shotgun analysis as described in the Materials and Methods. For each
group, three biological replicates have been tested (with 2 technical replicates per biological replicate).
Only proteins with significant differences in both iTop3 and iLFQ levels were regarded as differential.
Parameter Number
Unique peptides 207041
Non-redundant proteins 2558
Higher in tachyzoites 1325
Higher in MNCs 12
Similar levels in both 1221
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By deeper analysis, we identified 1337 proteins that were differential between both stages with
respect to both iTop3 and iLFQ parameters, as explained in Section 2.6. The large majority had lower
iLFQ and iTop3 levels in MNCs as compared to tachyzoites. Only 12 proteins had higher levels
(Table 2).
Unbiased analysis of the dataset by principal component analysis (PCA) demonstrated for both
iTop3 and iLFQ values (see Section 2.6) that the proteomes of tachyzoites and BKI-1294 induced MNCs
formed non-overlapping clusters separated by principal component 1 (PC1). Moreover, the proteomes
of biological and technical replicates clustered together for MNCs whereas the proteomes of biological
and technical replicates of tachyzoites were separated along PC2 (Figure 2).
Figure 2. Principal component analysis of proteome data sets from N. caninum tachyzoites and from
MNCs induced by BKI-1294 treatment. Tachyzoites and MNCs were grown, purified and subjected to
MS shotgun analysis as described in the Materials and Methods. All technical and biological replicates
are shown, namely red square, brown circle, and green triangle for tachyzoites (CTR), and pink circle,
blue square, and turquoise diamond for MNCs (M). (A) iTop3 data; (B) iLFQ data.
3.3. Multinucleated Complexes Express a Distinct Set of Potential Surface Antigens
A closer look at the 12 proteins with higher levels in MNCs compared to tachyzoites revealed that
seven proteins had N-terminally located signal peptides, and six proteins had one or more SRS-domains
(Table 3).
Table 3. List of proteins overexpressed in MNCs formed by BKI-1294 treatment of Neospora caninum
infected HFF monolayers. The NCLIV_ accession numbers in the ToxoDB database are given. IF,
translation initiation factor; SP, signal peptide; SRS, SAG1-related surface antigen; TM, transmembrane.
Accession No Annotation Protein Features and Properties
001830 Hypothetical protein SP; homologies to IF2 and collagen.
010030 Bradyzoite surface protein BSR4 SP; 2 SRS domains
010050 SRS domain-containing protein 2 SRS domains; homologies to 010030
019520 MGC83258 protein, related 1.7 MDa protein; homologies to ubiquitin ligase and mucin
019580 SRS domain-containing protein
SP, SRS domain, 2 TM domains, 1 lipoprotein domain,
homology to T. gondii, bradyzoite surface antigen.
Annotated as SAG4.
022800 Conserved hypothetical protein Homologies to serine-rich adhesion and collagen
035375 SRS domain-containing protein SP, 2 SRS domains
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Table 3. Cont.
Accession No Annotation Protein Features and Properties
044320 Zinc finger protein 467, related Homologies to serine-rich adhesins
044430 Hypothetical protein Short sequences with homologies to zinc finger proteins andATP-ase domain of Hsp90
061850 SRS domain-containing protein SP, TM domain, 4 SRS domains.
069001 SRS domain-containing protein SP, 2 SRS domains.
069110 Hypothetical protein SP
The relative abundance of these 12 proteins given by their respective iLFQ intensities—negligible
in tachyzoites—reached up to 108 iLFQ units in MNCs in the case of the SRS-domain containing protein
NCLIV_019580, formerly annotated as SAG4 (Figure 3).
Figure 3. Quantitative assessments of the proteins in tachyzoites (Tachy, white bars) and MNCs (MNCs,
black bars) listed in Table 3. For all proteins, mean values ± one standard deviation for LFQ intensities
(×106) in three biological replicates are shown. The proteins are termed by their respective accession
numbers in the ToxoDB.
These values were, however, more than two orders of magnitude lower than the amount of the
major surface antigen 1 of N. caninum, Nc SAG1 (NCLIV_033230). NcSAG1 reached 20.3 ± 1.3 × 109
iLFQ units in tachyzoites and 19.9 ± 0.7 × 109 iLFQ units in MNCs (Table S1).
3.4. The SRS Domain Containing Protein NCLIV_019580 (NcSAG4) Has Higher mRNA Expression Levels in
MNCs Compared to Tachyzoites
Since the SRS-domain containing protein encoded by NCLIV_019580, also annotated as NcSAG4,
had the highest differential protein level in MNCs (see Figure 2), we investigated whether the NcSAG4
protein levels were correlated to the respective mRNA expression levels. We compared the mRNA
levels in tachyzoites and MNCs of the corresponding coding sequence to N. caninum 28S RNA and
included three other transcripts, namely mRNA coding for BAG1, IMC1, and CDPK1, the target of
BKI-1294, into this comparison. As shown in Figure 4, MNCs had higher NcSAG4 mRNA levels
compared to tachyzoites.
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Figure 4. Quantitative assessments of mRNA levels of four selected genes. Confluent human foreskin
fibroblast monolayers were infected with N. caninum tachyzoites and left untreated for the generation of
tachyzoites (Tachy, white bars) or treated with BKI-1294 in order to generate MNCs (MNCs; black bars).
Cells were harvested, mRNA was extracted, cDNA was prepared, and mRNA levels were quantified
as described in Section 2.5. Mean ± standard error values from four replicates were assessed and
expression levels were given as values in arbitrary units relative to the amount of 28S rRNA. The genes
are termed by their respective accession numbers in ToxoDB.
The same was found for the expression level of mRNA coding for NcBAG1. The absolute mRNA
levels of BAG1 were, however, three magnitudes lower than those of the three other genes investigated.
Conversely, the levels of mRNAs encoding CDPK1 and IMC1 were lower in MNCs than in tachyzoites.
4. Discussion
The proteome dataset generated for this study, comparing protein expression in BKI-1294-induced
MNC and tachyzoites, contained 2558 non-redundant proteins, corresponding to 36% of the 7121 open
reading frames identified in the N. caninum genome [24], thus nearly two times more than the number
of proteins identified in a previous study [20].
In our comparative analysis of MNCs and tachyzoites, more than half of these proteins, including
key enzymes of energy and intermediary metabolism (see Table S1 for details), are downregulated
in MNCs induced by BKI-1294 treatment, and only twelve proteins are upregulated in MNCs.
This suggests that MNCs may represent a resting state of the parasite that is induced by drug pressure
exerted through BKI-1294 treatment.
This hypothesis is backed by the finding that mRNA coding for NcBAG1 (NCLIV_027470), also
known as a heat-shock protein and a well-established marker for bradyzoites [25], can be detected in
MNCs, but not in tachyzoites. The same has not only been observed in MNCs induced by BKI-1294 in
a previous study [12], but also in intracellular parasites exposed to a different class of compounds,
namely artemisinin derivatives such as artemisone and GC012 [22]. In addition, these findings were
confirmed on the protein level by observing increased anti-BAG1 antibody staining in HFF infected
with N. caninum and treated with these compounds [22]. The corresponding NcBAG1 protein is,
however, not included in the proteome dataset (see Table S1), suggesting that its expression levels are
below the resolution limit of the method. Conversely, two other bradyzoite antigens, namely the SRS
domain containing proteins NCLIV_010030, the bradyzoite antigen NcBSR4 [26], and NCLIV_019580,
formerly annotated as NcSAG4, are amongst the twelve MNC-upregulated proteins. Of these, NcSAG4
exhibits the highest expression levels.
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The N. caninum SRS domain containing protein superfamily comprises 227 genes and 52
pseudogenes [24], considerably more than Toxoplasma gondii strains [27]. The most prominent of these
proteins is certainly SAG1 (NCLIV_033230), the major surface antigen of N. caninum. During the last two
decades, NcSAG1 has been investigated as a candidate for recombinant vaccine development [28,29]
and for immunodiagnosis [30–32]. SAG1, considered an antigen expressed only in tachyzoites [33],
is expressed at equally high levels in tachyzoites and MNCs, and therefore would not account for an
immunological differentiation of both stages. Conversely, in our experiment, the bradyzoite-specific
NcSAG4 [34] is expressed in MNCs only, most likely by regulation on the transcriptional level. Similarly,
SAG4 expression has been shown to be upregulated in intracellular parasites treated with artemisinin
derivatives such as artemisone and GC007 [22]. However, these derivatives have a different mode
of action, and treatments of parasites induced completely different alterations. Nevertheless, also
artemisone and GC007 required in vitro treatments at a concentration of 5 µM over a period of over
20 days in order to act parasiticidal, similar to what has been observed for BKI-1294 [12]. Thus,
upregulation of NcSAG4 expression could be a general reaction to adverse physiological conditions,
similar to what has been postulated for bradyzoites and tissue cyst formation [35].
Besides SAG4, six other MNC-induced proteins contain signal peptides and thus may constitute
surface antigens, or secretory proteins involved in modulating the parasite-host interface. Five other
proteins have SRS-domains. These overexpressed proteins may constitute suitable candidates for
immunological investigations in vivo and—if this hypothesis could be confirmed—for recombinant
vaccine development.
Constitutive expression of NcSAG4 in N. caninum tachyzoites had been shown to confer protection
against vertical transmission in a mouse model [36]. Therefore, it is conceivable that the excellent
protective effects of BKI-1294 and related compounds against vertical transmission [12,14–16] may
be due to the induction of MNCs that express a set of diverse surface antigens, including NcSAG4.
However, we currently do not know whether these antigens are expressed on the surface of newly
formed zoites, or on the MNC surface. In any case, members of the SRS protein family are usually
anchored to the plasma membrane by a glycosylphosphatidylinositol (GPI) molecule [37,38]. Besides
NcSAG1 and NcSRS2 (also known as SRS29B and NcSRS29C, respectively), other SRS family members
have been studied, including NcSRS67 that has no orthologue in T. gondii [39], and NcSRS57, which is
expressed in both tachyzoites and bradyzoites [40,41]. However, according to our proteomics study,
none of these appear to be overexpressed in MNCs.
Two additional studies described the development of similar multinucleated forms of the closely
related T. gondii. Sugi et al. reported on another BKI named 1NM-PP1, which targeted T. gondii
mitogen-activated protein kinase-like 1 (TgMAPKL-1), interfered in the cell cycle, and induced the
formation enlarged multinucleated parasites. A mutation in a gatekeeper amino acid of TgMAPKL-1
led to a significant reduction in drug sensitivity and a reduction of enlarged multinucleated parasite
formation [42]. In another study, a targeted deletion of the rab11a gene in T. gondii (TGME49_289680)
also induced similar phenotypic changes [43]. The closest homologue in N. caninum, the unspecified
protein NCLIV_041930, is expressed at similar levels in both tachyzoites and BKI-1294 induced MNCs
(see Table S1).
Overall, we may consider that drug treatment, in the present case BKI-1294, does not only
cause a shutdown of housekeeping gene expression and morphological alterations, but may also
initiate “antigenic variation”, albeit to a much lesser extent than in other protozoan parasites such as
the apicomplexan Plasmodium sp. [44], the Excavata Trypanosoma sp. [45,46] and Giardia lamblia [47].
MNC formation may thus constitute a response strategy to ensure the survival in the presence of BKIs
and perhaps other compounds. Here, further investigations are required, also with respect to the
infective potential of these MNCs. It is noteworthy to mention that similar multinucleated stages were
induced upon in vitro treatment of T. gondii with diclazuril [48]. Diclazuril is triazinone derivative
that is effective against intracellular stages of Eimeria and Isospora spp. While the mechanism of this
drug is not well understood, it was shown that diclazuril is targeting enzymes of the respiratory
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chain and other enzymes such as dihydrofolate reductase (DHFR) [49]. However, we propose that
MNCs represent a stage designated as baryzoites (Greek βα%υσ = massive, bulky, heavy, inert) as they
represent a heavily enlarged parasitic stage that ensures survival of these parasites at increased drug
concentrations during prolonged periods of time.
Supplementary Materials: The following are available online at http://www.mdpi.com/2076-2607/8/6/801/s1,
Table S1. Proteome data set of N. caninum tachyzoites and of MNCs induced by BKI-1294 treatment of infected
cells. Parasites were grown and subjected to MS shotgun analysis as described in the Materials and Methods.
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